arrow_back Back to App

Faster Access to Innovative Medical Technologies for Seniors

This act aims to accelerate Medicare beneficiaries' access to new, breakthrough medical technologies. It will allow innovative medical devices to be made available to patients more quickly, potentially improving their healthcare quality and treatment outcomes. These changes are designed to ensure that the latest medical advancements reach those in need without unnecessary delays.
Key points
Expedited introduction of innovative medical devices into the Medicare program, meaning patients will have earlier access to them.
Enabling conditional approval for breakthrough medical devices under the Medicare New Technology Add-On Payment (NTAP) program, even if the full FDA approval process is not yet complete.
The changes are intended to be budget-neutral, meaning they should not generate additional costs for taxpayers within the Medicare program.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7939
Sponsor: Rep. Carey, Mike [R-OH-15]
Process start date: 2024-04-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Patient Access to Innovative New Technologies Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7939.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-04-11.

What are the main provisions?

Key points include:

  • Expedited introduction of innovative medical devices into the Medicare program, meaning patients will have earlier access to them.
  • Enabling conditional approval for breakthrough medical devices under the Medicare New Technology Add-On Payment (NTAP) program, even if the full FDA approval process is not yet complete.
  • The changes are intended to be budget-neutral, meaning they should not generate additional costs for taxpayers within the Medicare program.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Carey, Mike [R-OH-15].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health